Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, today reported the Robust Immune Response Phase IIb Data after which the GLSI stock price surged by
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) stock jumped vigorously in the post-market trading hours, as the shares jumped 31.75% to reach $75.23 following, a clinical-stage biotech
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.